Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What We Talk About When We Talk About Confirmatory Evidence

Jun 15 2017

• By Bridget Silverman

Related Content

FDA's First Step In Xenazine Review: Work Around Clinical Evidence Guidance

Mar 01 2009

Multiple Sclerosis Subtype 'Relatedness' Drove Debate On Ocrevus Approval

Jun 15 2017

When Is A Single Pivotal Trial “Robust” Enough? FDA’s Katz Offers Examples That Could Spell Trouble For Pfizer’s <em>Vyndaqel</em>

Jun 04 2012

SINGLE TRIALS WITH SIZE, POWERFUL STATISTICS OR CORROBATING ENDPOINTS MAY BE CONSIDERED AS SUPPORT FOR NDAs, FDA EXPLAINS IN EFFICACY EVIDENCE GUIDANCE

Mar 17 1997

Related Companies

Genentech, Inc.

Additional Topics

United States Review Pathway Drug Review Drug Approval Standards Regulation Drug Review Profile BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window